Back to search results

Qualia Senolytic Supplementation for Inflammation

This study is testing a dietary supplement called Qualia Senolytic to see if it can reduce inflammation in healthy adults. Researchers are looking for 40 participants, aged 45 to 79, who live in the United States. The main goal is to measure changes in specific inflammatory markers (like TNF and IL1B) in your blood after one week of taking the supplement. This is an open-label study, meaning both you and the researchers will know you are taking Qualia Senolytic. The study is currently unclear on its recruitment status.

Study design
This is an open-label pilot study involving 40 participants. It is an interventional study, meaning participants will receive Qualia Senolytic.
What's involved
You will take Qualia Senolytic for 7 days. You will provide blood samples via an at-home finger-prick kit at the beginning and end of the study, and complete electronic surveys on days 0, 3, and 7.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured at 1 week, which is the end of the 7-day study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06953518

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

Not Yet Recruiting
NAAges 45–79InterventionalBasic science
Qualia Life Sciences
~40 participants
Updated 2025-05-01 on ClinicalTrials.gov
What's tested:Qualia Senolytic

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Olink Target 48 Cytokine panel - TNF, IL1B, CXCL8, VEGFA
Measured over 1 week

Conditions

Inflammation

Explore related trials

Inflammation

Where it's being run

1 sites across 1 states
California1

Who to contact

William Scuba
[email protected]
855-281-2328
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide voluntary, written, informed consent to participate in the study
Agree to provide a valid cell phone number and are willing to receive communications through text.
Healthy adults 45 - 79 years of age Can read and write English
Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.
Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.
Willing to complete questionnaires, records, and diaries associated with the study.

Exclusion

Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
Known food intolerances/allergy to any ingredients in the product
Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
Having had a significant cardiovascular event in the past 6 months
Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
On immunosuppressive therapy
Individuals who were deemed incompatible with the test protocol
Adults lacking capacity to consent

What this trial measures

  • Olink Target 48 Cytokine panel - TNF, IL1B, CXCL8, VEGFA1 week

    Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA)